Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
50
BVS Quote, Financials, Valuation and Earnings
Last price:
$10.68
Seasonality move
:
-12.86%
Day range:
$10.36 - $10.71
52-week range:
$3.90 - $14.38
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.23x
P/B ratio:
4.69x
Volume:
213.1K
Avg. volume:
323.8K
1-year change:
104.21%
Market cap:
$698.1M
Revenue:
$512.3M
EPS (TTM):
-$0.60
Analysts' Opinion
-
Consensus RatingBioventus has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $15.00, Bioventus has an estimated upside of 40.45% from its current price of $10.68.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $13.00 representing 100% downside risk from its current price of $10.68.
Fair Value
-
According to the consensus of 3 analysts, Bioventus has 40.45% upside to fair value with a price target of $15.00 per share.
BVS vs. S&P 500
-
Over the past 5 trading days, Bioventus has underperformed the S&P 500 by -6.96% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Bioventus does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bioventus has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Bioventus reported revenues of $139M.
Earnings Growth
-
Bioventus has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Bioventus reported earnings per share of -$0.07.
Enterprise value:
1.1B
EV / Invested capital:
1.89x
Price / LTM sales:
1.23x
EV / EBIT:
45.64x
EV / Revenue:
1.94x
PEG ratio (5yr expected):
--
EV / Free cash flow:
37.07x
Price / Operating cash flow:
23.51x
Enterprise value / EBITDA:
33.73x
Gross Profit (TTM):
$371.9M
Return On Assets:
-4.96%
Net Income Margin (TTM):
-7.11%
Return On Equity:
-18.97%
Return On Invested Capital:
-6.61%
Operating Margin:
4.74%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $516.7M | $502.8M | $555.1M | $120.8M | $139M | |
| Gross Profit | $344.7M | $316.1M | $371.9M | $78.9M | $93.6M | |
| Operating Income | -$26.8M | -$11.3M | $17.6M | $3.7M | $6.6M | |
| EBITDA | -$103.1M | -$45.5M | $31.9M | $15.8M | $17M | |
| Diluted EPS | -$2.07 | -$2.94 | -$0.60 | -$0.12 | -$0.07 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $193.1M | $246.1M | $271.1M | $249.5M | $298.7M | |
| Total Assets | $479.3M | $654.8M | $1.4B | $811.1M | $769.5M | |
| Current Liabilities | $111.7M | $160.7M | $288.4M | $160.8M | $211.5M | |
| Total Liabilities | $333.9M | $424.3M | $1B | $584.6M | $582.7M | |
| Total Equity | $145.3M | $230.5M | $379.1M | $226.5M | $186.8M | |
| Total Debt | $193.3M | $177.4M | $424.4M | $394.6M | $383.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$5.7M | $10.2M | $29.8M | -$8.3M | $10.3M | |
| Cash From Investing | -$334.3M | $13M | -$1.7M | -$2M | -$64K | |
| Cash From Financing | $243.8M | -$32.1M | -$11.7M | $8.2M | $362K | |
| Free Cash Flow | -$28.6M | -$1.7M | $29M | -$10.4M | $10.3M | |
BVS
Sector
Market Cap
$698.1M
$46.1M
Price % of 52-Week High
74.27%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
-0.13%
-0.6%
1-Year Price Total Return
104.21%
-30.52%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$10.81
200-day SMA
Buy
Level
$8.41
Bollinger Bands (100)
Sell
Level
9.49 - 12.61
Chaikin Money Flow
Buy
Level
4.5M
20-day SMA
Sell
Level
$11.35
Relative Strength Index (RSI14)
Sell
Level
40.01
ADX Line
Sell
Level
24.57
Williams %R
Neutral
Level
-74.6914
50-day SMA
Sell
Level
$11.94
MACD (12, 26)
Sell
Level
-0.33
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Neutral
Level
75.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.2254)
Sell
CA Score
(Annual)
Level (-1.8601)
Buy
Beneish M-Score
(Annual)
Level (-3.5282)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (2.5608)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
Stock Forecast FAQ
In the current month, BVS has received 2 Buy ratings 1 Hold ratings, and 0 Sell ratings. The BVS average analyst price target in the past 3 months is $15.00.
-
Where Will Bioventus Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bioventus share price will rise to $15.00 per share over the next 12 months.
-
What Do Analysts Say About Bioventus?
Analysts are divided on their view about Bioventus share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bioventus is a Sell and believe this share price will drop from its current level to $13.00.
-
What Is Bioventus's Price Target?
The price target for Bioventus over the next 1-year time period is forecast to be $15.00 according to 3 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is BVS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bioventus is a Buy. 2 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BVS?
You can purchase shares of Bioventus via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bioventus shares.
-
What Is The Bioventus Share Price Today?
Bioventus was last trading at $10.68 per share. This represents the most recent stock quote for Bioventus. Yesterday, Bioventus closed at $10.68 per share.
-
How To Buy Bioventus Stock Online?
In order to purchase Bioventus stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
